Search Result

Results for "

leukemias and solid tumors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (1) Antifolate (1) Apoptosis (9) Aurora Kinase (1) Bcl-2 Family (1) Caspase (1) DNA/RNA Synthesis (1) Drug Derivative (1) E1/E2/E3 Enzyme (2) Epigenetic Reader Domain (1) FAK (1) HDAC (1) MDM-2/p53 (3) MHC (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (3) Nucleoside Antimetabolite/Analog (2) Oxidative Phosphorylation (2) PKC (1) ROS Kinase (1) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (17) Inflammation/Immunology (2) Metabolic Disease (1)

By Targets:

Anaplastic lymphoma kinase (ALK) (1)

Antifolate (1)

Apoptosis (9)

Aurora Kinase (1)

Bcl-2 Family (1)

Caspase (1)

DNA/RNA Synthesis (1)

Drug Derivative (1)

E1/E2/E3 Enzyme (2)

Epigenetic Reader Domain (1)

FAK (1)

HDAC (1)

MDM-2/p53 (3)

MHC (1)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (3)

Nucleoside Antimetabolite/Analog (2)

Oxidative Phosphorylation (2)

PKC (1)

ROS Kinase (1)

Transmembrane Glycoprotein (1)

By Research Areas:

Cancer (17)

Inflammation/Immunology (2)

Metabolic Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Fat Mass and Obesity-associated Protein (FTO)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N2732

6-Prenylapigenin 6-Prenyl-4',5,7-trihydroxyflavone; 6-C-Prenylapigenin	Others	Cancer
6-Prenylapigenin is a biologically active flavonoid with anti-tumor activity and antiangiogenic properties. 6-Prenylapigenin exerts cytotoxicity against cancer cells, such as leukemia and solid cancer cells .

HY-106014

Tezacitabine	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Apoptosis	Cancer
Tezacitabine is a cytostatic and cytotoxic antimetabolite and a nucleoside analogue. Tezacitabine irreversibly inhibits the ribonucleotide reductase and interferes with DNA replication and repair. Tezacitabine effectively induces cells apoptotic. Tezacitabine has the potential for leukemias and solid tumors (carcinomas) treatment .

HY-101266B

Milademetan tosylate hydrate 5 Publications Verification DS-3032b; DS-3032 tosylate hydrate	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
Milademetan (DS-3032) tosylate hydrate is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) tosylate hydrate induces G1 cell cycle arrest, senescence and apoptosis .

HY-101266

Milademetan 5 Publications Verification DS-3032	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
Milademetan (DS-3032) is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) induces G1 cell cycle arrest, senescence and apoptosis .

HY-19171

Aranose	Drug Derivative	Cancer
Aranose is a nitrosourea derivative with antineoplastic activity. Aranose can be used for leukemia, plasmacytoma, and solid tumor research .

HY-P991558

RO-5429083 RG-7356	Transmembrane Glycoprotein	Cancer
RO-5429083 is a humanized monoclonal antibody inhibitor targeting CD44. RO-5429083 can be used for acute myeloid leukemia (AML) and solid tumors research .

HY-135254

CP-46665 dihydrochloride CP-46665-1	PKC	Cancer
CP-46665 dihydrochloride is an anticancer agent that inhibits the incorporation of tritiated thymidine into leukemia cells and human solid tumor cells in vitro. It can lead to the loss of surface characteristics in tumor cells and disrupt cell membranes, inhibiting cell proliferation .

HY-19095

TNP-351	Antifolate	Cancer
TNP-351 is an antifolate. TNP-351, a dihydrofolate reductase (DHFR) inhibitor, has potent antitumor activity against not only leukemia cells but also solid tumor cells in vitro and in vivo .

HY-P11084

WT1 126-134 peptide	MHC	Inflammation/Immunology Cancer
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (K_d = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .

HY-106218

Flurocitabine 5-Fluorocyclocytidine; 5'-Fluorocyclocytidine	Nucleoside Antimetabolite/Analog	Cancer
Flurocitabine (5-Fluorocyclocytidine) is a fluorinated anlydride analog of cytosine arabinoside, partially hydrolysecl in vivo into two active antitumor substances (arabinosyl-tluorocytosine (ara-FC) and arabinosyl-fluorouracil (ara-FU)). Flurocitabine (5-Fluorocyclocytidine) has antitumor activity during phase I studies in acute leukemia and solid tumors .

HY-112037A

IACS-010759 hydrochloride Maximum Cited Publications 16 Publications Verification IACS-10759 hydrochloride	Oxidative Phosphorylation Mitochondrial Metabolism Apoptosis	Cancer
IACS-010759 hydrochlorideis an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 hydrochlorideinhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 hydrochloride has the potential for relapsed/refractory AML and solid tumors research .

HY-112037

IACS-010759 Maximum Cited Publications 16 Publications Verification IACS-10759	Oxidative Phosphorylation Mitochondrial Metabolism Apoptosis	Cancer
IACS-010759 is an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 inhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 has the potential for relapsed/refractory AML and solid tumors research .

HY-158618

Aurora kinase inhibitor-14	Aurora Kinase Apoptosis	Cancer
Aurora kinase inhibitor-14 (Compound 79) is an orally active and highly selective inhibitor of Aurora kinases with IC₅₀ values of 0.5 nM and 1.2 nM for Aurora A and Aurora B, respectively. Aurora kinase inhibitor-14 binds to the ATP-binding site of Aurora kinases to block chromosome segregation during mitosis and induce apoptosis in tumor cells. Aurora kinase inhibitor-14 is promising for research of various solid tumors and hematological malignancies, such as non-small cell lung cancer, breast cancer, and acute myeloid leukemia .

HY-155163

APG-2449	Anaplastic lymphoma kinase (ALK) ROS Kinase FAK Apoptosis	Cancer
APG-2449 is an orally active inhibitor for BCL-2 and multikinase (ALK/FAK/ROS1) with potent antitumor activities. APG-2449 reduces cell viability and enhances apoptosis in acute myeloid leukemia cells in vitro. APG-2449 decreases activation of FAK and its downstream effectors. APG-2449 can be studied in research for mesothelioma tumor, non-small cell lung cancer, ovarian cancer, hematologic and solid malignancies .

HY-175332

Apoptosis inducer 43	Apoptosis Bcl-2 Family Caspase MDM-2/p53	Cancer
Apoptosis inducer 43 is an apoptosis inducer. Apoptosis inducer 43 can induce apoptosis, SubG0-G1 cell cycle arrest, secondary necrosis, and upregulate caspase-3, p53, and Bax/Bcl-2 expression in HCT116 cells. Apoptosis inducer 43 can inhibit tumor growth in a solid Ehrlich carcinoma (SEC) mouse model. Apoptosis inducer 43 can be used to study cancers such as colon cancer, leukemia, and non-small cell lung cancer .

HY-150772

Tubulin/HDAC-IN-1	Microtubule/Tubulin HDAC Apoptosis Mitochondrial Metabolism	Cancer
Tubulin/HDAC-IN-1 is a dual tubulin and HDAC-IN-1 inhibitor through CH/π interaction with tubulin and hydrogen bond interaction with HDAC8. Tubulin/HDAC-IN-1 inhibits tubulin polymerization and selectively inhibits HDAC8 (IC₅₀: 150 nM). Tubulin/HDAC-IN-1 has cytotoxicity against various human cancer cells, also arrests cell cycle in the G2/M phase and induces cell apoptosis. Tubulin/HDAC-IN-1 can be used in the research of hematologic and solid tumors such as neuroblastoma, leukemia .

HY-150105

Icovamenib BMF-219; Menin-MLL inhibitor 21	Epigenetic Reader Domain	Metabolic Disease Inflammation/Immunology Cancer
Icovamenib (BMF-219) is a selective, orally active, irreversible Menin inhibitor. Icovamenib forms a stable and irreversible covalent bond with Menin. Icovamenib promotes selective and controlled proliferation of beta cells and improvement of beta cell function in ex vivo human islet cultures. Icovamenib enhances glycemic control in animal diabetic models. Icovamenib induces a dose-dependent enhancement in insulin secretion potentiated by the GLP-1 RA. Icovamenib can be used for the study of multiple hematologic malignancies, solid tumors, and diabetes mellitus, such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia and type 2 diabetes .

Cat. No.	Product Name	Target	Research Area

HY-P11084

WT1 126-134 peptide	MHC	Inflammation/Immunology Cancer
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (K_d = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .

Cat. No.	Product Name	Target	Research Area

HY-P991558

RO-5429083 RG-7356	Transmembrane Glycoprotein	Cancer
RO-5429083 is a humanized monoclonal antibody inhibitor targeting CD44. RO-5429083 can be used for acute myeloid leukemia (AML) and solid tumors research .

6-Prenylapigenin 6-Prenyl-4',5,7-trihydroxyflavone; 6-C-Prenylapigenin	Structural Classification Flavonoids Flavones Source classification Maclura pomifera (Raf.) Schneid. Plants Moraceae	Others
6-Prenylapigenin is a biologically active flavonoid with anti-tumor activity and antiangiogenic properties. 6-Prenylapigenin exerts cytotoxicity against cancer cells, such as leukemia and solid cancer cells .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks